Key facts
- This page summarizes Edward J. Sitar's Form 4 filing for 9 METERS BIOPHARMA, INC..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 15 Sep 2021, 08:12.
Edward J. Sitar - 14 Sep 2021 Form 4 Insider Report for 9 METERS BIOPHARMA, INC.
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 14 Sep 2021
- Net transaction value
- +$18,300
- SEC form
- 4
- Accepted by SEC
- 15 Sep 2021, 08:12:38 UTC
- Prior SEC filing
- 06 Jul 2021
- Next SEC filing
- 24 Nov 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Edward J. Sitar
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Edward J. Sitar filed Form 4 for 9 METERS BIOPHARMA, INC. on 15 Sep 2021.
Change
- Previous filing in this sequence was filed on 06 Jul 2021.
- Current net transaction value: +$18,300.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NMTR
transaction
Common stock
Purchase
- Transaction value
- $18,300
- Shares
- +15,000
- Change %
- +8.4%
- Price
- $1.22*
- Shares after
- 194,338
- Date
- 14 Sep 2021
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.215 to $1.22, inclusive. The reporting person undertakes to provide to 9 Meters Biopharma, Inc., any security holder of 9 Meters Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.